Evidence map›Paper›PMID 35746449›Full record

ArticleVaccines2022

Success of Current COVID-19 Vaccine Strategies vs. the Epitope Topology of SARS-CoV-2 Spike Protein-Receptor Binding Domain (RBD): A Computational Study of RBD Topology to Guide Future Vaccine Design.

Santhinissi Addala, Madhuri Vissapragada, Madhumita Aggunna, Niharikha Mukala, Manisha Lanka, Shyamkumar Gampa, Manikanta Sodasani, Jahnavi Chintalapati, Akhila Kamidi, Ravindra P Veeranna and 1 more

Abstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Santhinissi AddalaStem Cell Biology Branch, Department of Intramural Research Core, The Center for Advanced-Applied Biological Sciences & Entrepreneurship (TCABS-E), Visakhapatnam 530016, India.
Madhuri VissapragadaSynthetic Biology Branch, Department of Intramural Research Core, The Center for Advanced-Applied Biological Sciences & Entrepreneurship (TCABS-E), Visakhapatnam 530016, India.
Madhumita AggunnaMultiomics-Oncology & Immunotherapy Branch, Department of Intramural Research Core, The Center for Advanced-Applied Biological Sciences & Entrepreneurship (TCABS-E), Visakhapatnam 530016, India.ORCID 0000-0003-0174-2965
Niharikha MukalaMultiomics-Infectious Diseases Branch, Department of Intramural Research Core, The Center for Advanced-Applied Biological Sciences & Entrepreneurship (TCABS-E), Visakhapatnam 530016, India.
Manisha LankaDepartment of Intramural Research Core, The Center for Advanced-Applied Biological Sciences & Entrepreneurship (TCABS-E), Visakhapatnam 530016, India.
Shyamkumar GampaDepartment of Intramural Research Core, The Center for Advanced-Applied Biological Sciences & Entrepreneurship (TCABS-E), Visakhapatnam 530016, India.
Manikanta SodasaniDepartment of Intramural Research Core, The Center for Advanced-Applied Biological Sciences & Entrepreneurship (TCABS-E), Visakhapatnam 530016, India.
Jahnavi ChintalapatiDepartment of Intramural Research Core, The Center for Advanced-Applied Biological Sciences & Entrepreneurship (TCABS-E), Visakhapatnam 530016, India.
Akhila KamidiDepartment of Intramural Research Core, The Center for Advanced-Applied Biological Sciences & Entrepreneurship (TCABS-E), Visakhapatnam 530016, India.
Ravindra P VeerannaDepartment of Biochemistry, Central Food Technological Research Institute, Mysore 570020, India.ORCID 0000-0003-4228-1843
Ravikiran S YedidiStem Cell Biology Branch, Department of Intramural Research Core, The Center for Advanced-Applied Biological Sciences & Entrepreneurship (TCABS-E), Visakhapatnam 530016, India.ORCID 0000-0003-2755-1307

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease-2019 (COVID-19) is a pandemic with a high morbidity rate occurring over recent years. COVID-19 is caused by the severe acute respiratory syndrome causing coronavirus type-2 (SARS-CoV-2). COVID-19 not only challenged mankind but also gave scope to the evolution of various vaccine design technologies. Although these vaccines protected and saved many lives, with the emerging viral strains, some of the strains may pose a threat to the currently existing vaccine design that is primarily based on the wild type spike protein of SARS-CoV-2. To evaluate the risk involved from such mutant viral strains, we performed a systematic in silico amino acid substitution of critical residues in the receptor binding domain (RBD) of the spike protein. Our molecular modeling analysis revealed significant topological changes in the RBD of spike protein suggesting that they could potentially contribute to the loss of antigen specificity for the currently existing therapeutic antibodies/vaccines, thus posing a challenge to the current vaccine strategies that are based on wild type viral spike protein epitopes. The structural deviations discussed in this article should be considered carefully in the future vaccine design.

Indexed as

ACE-2 receptorCOVID-19epitopeSARS CoV-2spike proteinvaccines

Identifiers

PMID35746449
PMCPMC9228374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.